The FDA has granted accelerated approval to atezolizumab (Tecentriq) for the treatment of locally advanced or metastatic urothelial carcinoma—the most common type of bladder cancer.
Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.
Loss of function of the PTEN tumor suppressor gene leads to resistance to therapies targeting the Notch signaling pathway according to a mouse study presented at the 2016 Society of Gynecologic Oncology annual meeting, held in San Diego, March 19-22, 2016.
Detection of an epigenetic signature found in five different common tumor types—colon, lung, breast, stomach, and endometrial cancers—may be useful in diagnosing early-stage tumors using a blood test.
ASCO has published a guideline on biomarker use to guide decisions for adjuvant systemic treatment for women with early-stage, invasive breast cancer.
Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.
Dose-determining phase I clinical trials may not correctly determine the appropriate doses of small molecule oncology drugs to administer in larger, later stage trials.
We are speaking with Maximilian Diehn, MD, PhD, on developing genomics-based biomarkers to identify the presence of cancer cells for prognosis and predicting response to cancer therapies.
The targeted, oral therapy crizotinib (Xalkori), has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have c-ros oncogene 1 (ROS1)-rearranged tumors.
On December 11, 2015, the US Food and Drug Administration (FDA) approved alectinib for patients with ALK-rearrangement positive non-small cell lung cancer (NSCLC) that is refractory to another ALK-targeted oral drug, crizotinib.